It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

¹**Neurohistopathological Findings of the Brain Parenchyma After Long-Term Deep Brain** ²**Stimulation: Case Series and Systematic Literature Review**

- 3 **AUTHORS**
4 Juan Vivanco-Suarez^{1*}, MD; Timothy Woodiwiss^{1*}, MD; Kimberly L. Fiock², PhD; Marco M. Hefti²,
5 MD: Nandakumar S. Narayanan³ MD, PhD: Jeremy D. W. Greenlee¹ MD
- MD; Nandakumar S. Narayanan³, MD, PhD; Jeremy D. W. Greenlee¹, MD
6. * Both authors contributed equally
- ^{*} Both authors contributed equally.
- $\frac{7}{8}$

8 **AFFILIATIONS**
9 ¹ Department of No

- ¹ Department of Neurosurgery, University of Iowa, Iowa City, IA, United States

² Department of Pathology, University of Iowa, Iowa City, IA, United States
- 2 Department of Pathology, University of Iowa, Iowa City, IA, United States.
21 ³ Department of Neurology, University of Iowa, Iowa City, IA, United States.
- $\frac{3}{12}$ Department of Neurology, University of Iowa, Iowa City, IA, United States.
- 12
13

13 **CORRESPONDENCE**
14 **Jeremy D. W. Greenlee.**

- 14 Jeremy D. W. Greenlee, MD,
15 Department of Neurosurgery,
- 15 Department of Neurosurgery, University of Iowa Hospitals and Clinics,
16 200 Hawkins Dr. 1826 JPP, Iowa City, IA 52242, United States.
- 16 200 Hawkins Dr, 1826 JPP, Iowa City, IA 52242, United States.
17 E-mail address: ieremy-greenlee@ujowa.edu, phone: (319) 356-2
- 17 E-mail address: *jeremy-greenlee@uiowa.edu*, phone: (319) 356-2771
18
-

18 19 **SHORT RUNNING TITLE**
20 Neurohistopathological findin

- 20 Neurohistopathological findings after deep brain stimulation
21
-

22 22 **KEYWORDS**
23 Parkinson's dis

- 23 Parkinson's disease; Neuropathology; Gliosis; Postmortem 24
-

25 25 **ELEMENTS COUNTS**
26 **Abstract:** 302 words

- 26 Abstract: 302 words
27 Text: 3529 words
- 27 Text: 3529 words
28 References: 48
- 28 References: 48
29 Tables: 2
- 29 Tables: 2
30 Figures: 1
- 30 Figures: 1
31 Suppleme
- 31 Supplemental tables: 5
32 Supplemental figures: 0
- 32 Supplemental figures: 0
33
-

33 ³⁴**PREVIOUS PRESENTATION**

35 None
36

$37⁵$

- ³⁷**ETHICS**
- 38 None
39

40 40 **CONFLICTS OF INTEREST**
41 The authors report no disclosure

- 41 The authors report no disclosures.
42
-
- 42 43 **FUNDING**
44 This researc
- 44 This research received no specific grant from any funding agency in public, commercial, or not-for-profit sectors.
- sectors.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

⁴⁶**Neurohistopathological Findings of the Brain Parenchyma After Long-Term Deep Brain**

⁴⁷**Stimulation: Case Series and Systematic Literature Review**

⁴⁸**ABSTRACT**

- *Introduction:* The efficacy of deep brain stimulation (DBS) has been established to treat several
50 movement and psychiatric disorders. However, several aspects, such as the mechanism of action
- 50 movement and psychiatric disorders. However, several aspects, such as the mechanism of action and
51 tissue changes after treatment are incompletely described. Hence, we aimed to describe the
- 51 tissue changes after treatment are incompletely described. Hence, we aimed to describe the
52 neurohistopathological findings of 9 patients who underwent DBS for movement disorders.
- 52 neurohistopathological findings of 9 patients who underwent DBS for movement disorders. Additionally,
53 we performed a systematic literature review on postmortem studies after DBS implantation.
- 53 we performed a systematic literature review on postmortem studies after DBS implantation.
54 *Methods*: We performed a retrospective study of patients who underwent DBS for movemer
- **14 S4** *Methods:* We performed a retrospective study of patients who underwent DBS for movement disorders between 2000-2023 and had postmortem autopsy. Demographics, clinical features, and outcomes were
- 55 between 2000-2023 and had postmortem autopsy. Demographics, clinical features, and outcomes were
56 collected. Levodopa equivalent daily dose (LEDD) and total electrical energy delivered (TEED) were
- 56 collected. Levodopa equivalent daily dose (LEDD) and total electrical energy delivered (TEED) were
57 calculated. Neurohistopathological assessments were performed from autopsies. A systematic literature
- 57 calculated. Neurohistopathological assessments were performed from autopsies. A systematic literature
58 review was conducted to summarize the literature.
- 58 review was conducted to summarize the literature.
59 **Results:** Postmortem neurohistopathologic assessm
- **Results:** Postmortem neurohistopathologic assessment of 9 patients who underwent DBS for movement disorders (8 Parkinson's disease [multiple system atrophy was final diagnosis in 1], and 1 parkinsonism)
- 60 disorders (8 Parkinson's disease [multiple system atrophy was final diagnosis in 1], and 1 parkinsonism)
61 was performed. Median age at DBS implantation was 65 years (range, 54-69), and most were male (8
- 61 was performed. Median age at DBS implantation was 65 years (range, 54-69), and most were male (8
62 patients, 89%). Most common DBS target was the subthalamic nucleus (8 patients, 89%). Median DB
-
- 62 patients, 89%). Most common DBS target was the subthalamic nucleus (8 patients, 89%). Median DBS
63 duration was 65 months (range, 7-264 months). Post-DBS reduction in LEDD was found in 7/9 patients 63 duration was 65 months (range, 7-264 months). Post-DBS reduction in LEDD was found in 7/9 patients,
64 and TEED was increased over time in 5/7 patients. No patients died due to DBS. Neurohistopathological
- 64 and TEED was increased over time in 5/7 patients. No patients died due to DBS. Neurohistopathological
65 assessment showed gliosis in 7 (78%) patients and activated microglial infiltration in 1 (11%).
- 65 assessment showed gliosis in 7 (78%) patients and activated microglial infiltration in 1 (11%).
66 Additionally, postmortem findings (after DBS) of 59 patients (between 1977-2021) were identi-
- 66 Additionally, postmortem findings (after DBS) of 59 patients (between 1977-2021) were identified in the
67 literature: 26 (44%) for Parkinson's disease, 20 (34%) for pain, and 13 (22%) for other conditions.
- 67 literature: 26 (44%) for Parkinson's disease, 20 (34%) for pain, and 13 (22%) for other conditions.
68 **Conclusion:** Our findings confirm the presence of a local tissue reaction, including gliosis and action
- 68 Conclusion: Our findings confirm the presence of a local tissue reaction, including gliosis and activated
69 microglial infiltration around the implanted DBS electrodes. The effect of the local changes on the
- 69 microglial infiltration around the implanted DBS electrodes. The effect of the local changes on the
6 clinical efficacy of DBS is not established. Further DBS postmortem studies and standardization of
- 70 clinical efficacy of DBS is not established. Further DBS postmortem studies and standardization of tissue
71 processing are needed.
- 71 processing are needed.
72
-

73 **ABBREVIATIONS**
74 DBS. deep brain stim

- 74 DBS, deep brain stimulation; LEDD, Levodopa equivalent daily dose; MSA, multiple system atrophy;
75 PD, Parkinson's disease: TEED, total electrical energy delivered.
- 75 PD, Parkinson's disease; TEED, total electrical energy delivered.
76
-

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

77 **INTRODUCTION**
78 The efficacy of The efficacy of deep brain stimulation (DBS) has been established for the treatment of several
The movement and psychiatric disorders.¹ Furthermore, its experimental application for chronic pain, ob movement and psychiatric disorders.¹ Furthermore, its experimental application for chronic pain, obesity,
and other neurocognitive disorders has continually expanded, aiming to benefit a broader group of 80 and other neurocognitive disorders has continually expanded, aiming to benefit a broader group of
81 batients.² However, several aspects of this treatment are not completely defined, including the spec 81 patients.² However, several aspects of this treatment are not completely defined, including the specific
82 interaction and activation of surrounding structures, the local tissue changes in the brain caused by lons 82 interaction and activation of surrounding structures, the local tissue changes in the brain caused by long-
83 term stimulation, the potential adverse tissue responses induced by the electrode, and the existence of 83 term stimulation, the potential adverse tissue responses induced by the electrode, and the existence of neuronal damage.^{1,3} A deeper understanding of the chronic local glial responses after electrode neuronal damage.^{1,3} A deeper understanding of the chronic local glial responses after electrode
85 implantation may provide helpful insights for the improvement of anatomical targets and the or 85 implantation may provide helpful insights for the improvement of anatomical targets and the optimization
86 of electrode design according to the target tissue. 86 of electrode design according to the target tissue.
87 Previously published postmortem studies has

87 Previously published postmortem studies have begun the characterization of histological changes
88 occurring around electrodes in response to implantation and chronic stimulation. A comprehensive rev 88 occurring around electrodes in response to implantation and chronic stimulation. A comprehensive review
89 oerformed by DiLorenzo et al. reported 40 cases with implanted systems from as early as 1977.⁴ The performed by DiLorenzo et al. reported 40 cases with implanted systems from as early as 1977.⁴ The
90 authors showed that in more than 50% of the cases, there was local fibrosis, astrocytosis, multinuclea 90 authors showed that in more than 50% of the cases, there was local fibrosis, astrocytosis, multinucleated
91 giant cells. mononuclear leukocytes, macrophages, activated microglia, and neuronal loss.^{4,5} Of note. giant cells, mononuclear leukocytes, macrophages, activated microglia, and neuronal loss.^{4,5} Of note,
92 persistent efficacy was more commonly observed when tissue injury was absent. More recently, Veda 92 persistent efficacy was more commonly observed when tissue injury was absent. More recently, Vedam-
93 Mai et al. found that 3 out of 4 DBS cases exhibited histopathological evidence of a glial collar or scar 93 Mai et al. found that 3 out of 4 DBS cases exhibited histopathological evidence of a glial collar or scar
94 around the electrode, but there was no significant association between DBS duration and the amount of 94 around the electrode, but there was no significant association between DBS duration and the amount of gliosis. As the technologies and technologies employed for DBS continue to evolve, the evidence regarding 95 gliosis. As the technologies and techniques employed for DBS continue to evolve, the evidence regarding the local changes around the electrode is contradictory.⁶⁻⁹ For instance, data on the comparison of the local changes around the electrode is contradictory.⁶⁻⁹ For instance, data on the comparison of histological samples from patients with active and inactive electrodes is limited, the effect of the s 97 histological samples from patients with active and inactive electrodes is limited, the effect of the size of
98 the gliotic scar is uncertain, and evidence of the distance (from the electrode) where neuronal loss or 98 the gliotic scar is uncertain, and evidence of the distance (from the electrode) where neuronal loss or preservation is observed is unclear.¹⁰ 99 preservation is observed is unclear.¹⁰
100 Hence, this study aims to charac

100 Hence, this study aims to characterize and describe the neurohistopathological environment of the
101 brain parenchyma surrounding DBS electrodes in 9 patients who underwent surgical treatment for 101 brain parenchyma surrounding DBS electrodes in 9 patients who underwent surgical treatment for
102 Parkinson's disease (PD) or a parkinsonism syndrome. Additionally, we present an updated and exp 102 Parkinson's disease (PD) or a parkinsonism syndrome. Additionally, we present an updated and expanded
103 ummary of the literature on this topic with a systematic review of postmortem studies after DBS 103 summary of the literature on this topic with a systematic review of postmortem studies after DBS
104 implantation. 104 implantation.
105

106 **METHODS**
107 **Study design**

107 **Study design, patient protocol, tissue acquisition, and storage**
108 This was a retrospective study of adult patients who underwe

This was a retrospective study of adult patients who underwent DBS for movement disorders at a 109 tertiary academic center between July 2000 and April 2023. All tissue was obtained from autopsies
110 conducted at the University of Iowa Hospitals and Clinics as part of routine clinical care in accordancy ¹¹⁰conducted at the University of Iowa Hospitals and Clinics as part of routine clinical care in accordance

³

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

111 with all applicable federal and state laws and regulations. Consent for the use of tissue in research was
112 obtained from the next of kin as part of the autopsy consent. This project was reviewed by the Universi-112 obtained from the next of kin as part of the autopsy consent. This project was reviewed by the University
113 of Iowa Institutional Review Board and determined not to represent human subjects research under the 113 of Iowa Institutional Review Board and determined not to represent human subjects research under the
114 National Institutes of Health Revised Common Rule. Based on the database created for each donor, for 114 National Institutes of Health Revised Common Rule. Based on the database created for each donor, for
115 this study, we extracted the age at diagnosis, sex, duration of disease, calculated Levodopa equivalent this study, we extracted the age at diagnosis, sex, duration of disease, calculated Levodopa equivalent daily dose $(LEDD)^{11}$ (before implantation, 6 [\pm 3] months after DBS, and at last clinical follow-up), age
117 at DBS implantation, intraoperative and hospitalization complications, DBS duration, post-implantation at DBS implantation, intraoperative and hospitalization complications, DBS duration, post-implantation 118 stimulation parameters (at 6 [\pm 3] months after DBS, at last clinical follow-up), and age at death. To
119 assess the stimulation parameters, we calculated total electrical energy delivered (TEED)¹² (impedan assess the stimulation parameters, we calculated total electrical energy delivered (TEED)¹² (impedance was set to 1000Ω to standardize calculations).

120 was set to 1000Ω to standardize calculations).
121

122 Neurohistopathological techniques and evaluation
123 Tissue processing was done as previously describ Tissue processing was done as previously described.¹³⁻¹⁵ Briefly, brains were fixed in 20% neutral
124 buffered formalin for 10-14 days and then sectioned, sampled, processed, and stained (both histochemic 124 buffered formalin for 10-14 days and then sectioned, sampled, processed, and stained (both histochemical
125 and immunohistochemical stains) in the Emory Warner Clinical Pathology Laboratories of the University and immunohistochemical stains) in the Emory Warner Clinical Pathology Laboratories of the University 126 of Iowa according to standard protocols. A board-certified neuropathologist (MMH) and PhD-trained
127 esearch neuropathologist (KLF) reviewed all tissue sections and stains. research neuropathologist (KLF) reviewed all tissue sections and stains.

128
129 129 **Systematic literature review and data extraction**
130 A comprehensive literature search of the MEDI

130 A comprehensive literature search of the MEDLINE (via PubMed) database using medical subject
131 heading terms, entrees, and free text to identify all published postmortem neurohistopathological reports 131 heading terms, entrees, and free text to identify all published postmortem neurohistopathological reports
132 of DBS cases (end-of-search date: August 9, 2023). The complete search strategy is found in 132 of DBS cases (end-of-search date: August 9, 2023). The complete search strategy is found in
133 **Supplemental Table 1**. All DBS cases, regardless of indication or anatomical target in the hu **Supplemental Table 1**. All DBS cases, regardless of indication or anatomical target in the human brain, were included. Review articles or meta-analyses that did not describe disaggregated data on DBS cases 134 were included. Review articles or meta-analyses that did not describe disaggregated data on DBS cases
135 were excluded. Two independent reviewers (TW and JV-S) screened the articles using the Rayyan tool 135 were excluded. Two independent reviewers (TW and JV-S) screened the articles using the Rayyan tool
136 (https://www.rayyan.ai/). Any difference between reviewers was settled through discussion. After the ¹³⁶(https://www.rayyan.ai/). Any difference between reviewers was settled through discussion. After the 137 initial selection of eligible studies, the reference lists were thoroughly searched to identify additional
138 eligible studies based on the "snowball" methodology.¹⁶ Because DiLorenzo et al. thoroughly review eligible studies based on the "snowball" methodology.¹⁶ Because DiLorenzo et al. thoroughly reviewed
139 the literature in 2014, we expanded our review to new cases either missed by the aforementioned authors 139 the literature in 2014, we expanded our review to new cases either missed by the aforementioned authors
140 or reported after the review was completed. The following data were collected using a standardized data 140 or reported after the review was completed. The following data were collected using a standardized data
141 vextraction form: demographic and patient characteristics, information about implanted hardware, 141 extraction form: demographic and patient characteristics, information about implanted hardware,
142 stimulation parameters, clinical course, and neuropathological findings. Clinical efficacy and dec 142 stimulation parameters, clinical course, and neuropathological findings. Clinical efficacy and decline after
143 DBS were extracted as defined by the authors of each study. When critical or disaggregated information 143 DBS were extracted as defined by the authors of each study. When critical or disaggregated information
144 was missing, the studies were excluded. was missing, the studies were excluded.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

145

146 **RESULTS**
147 **Patient den**

147 Patient demographics, clinical, and DBS characteristics
148 A total of 9 patients who had DBS implantation were is

148 148 A total of 9 patients who had DBS implantation were identified from our institutional autopsy
149 database. The patient and neurohistopathologic characteristics are described in **Table 1**. The mediar 149 database. The patient and neurohistopathologic characteristics are described in **Table 1**. The median age
150 of disease onset was 52 (range, 47-64 years), and 8 (89%) were male. On preoperative clinical evaluation 150 of disease onset was 52 (range, 47-64 years), and 8 (89%) were male. On preoperative clinical evaluation,
151 PD was diagnosed in 8 (89%) patients and parkinsonism in 1 (11%). Of note, patient 9 presented 151 PD was diagnosed in 8 (89%) patients and parkinsonism in 1 (11%). Of note, patient 9 presented
152 clinically as PD with a very robust response to levodopa for several years. However, dysautonom 152 clinically as PD with a very robust response to levodopa for several years. However, dysautonomic
153 symptoms and ataxia emerged throughout the disease course, pointing to the diagnosis of a slowly 153 symptoms and ataxia emerged throughout the disease course, pointing to the diagnosis of a slowly
154 verolying Parkinsonian variant multiple system atrophy (MSA), which was confirmed on postmorte 154 evolving Parkinsonian variant multiple system atrophy (MSA), which was confirmed on postmortem
155 neurohistopathologic evaluation. 155 neurohistopathologic evaluation.
156 Regarding the DBS characte Regarding the DBS characteristics, the median disease course before DBS implantation was 7 years 157 (range, 3-20 years). The median patient age at DBS implantation was 65 years (range, 54-69 years). All patients received bilateral DBS lead implantation; the majority received electrodes targeting the bilateral 158 patients received bilateral DBS lead implantation; the majority received electrodes targeting the bilateral
159 subthalamic nuclei (8, 89%). One (11%) patient received leads targeting the globus pallidus interna. 159 subthalamic nuclei (8, 89%). One (11%) patient received leads targeting the globus pallidus interna.
160 Patient 3 had an additional lead implanted in the left ventralis intermedius thalamic nucleus due to 160 Patient 3 had an additional lead implanted in the left ventralis intermedius thalamic nucleus due to
161 refractory right-sided tremor. All electrodes were made of platinum/iridium (Medtronic, Inc.). The 161 refractory right-sided tremor. All electrodes were made of platinum/iridium (Medtronic, Inc.). The
162 median DBS duration was 65 months (range, 7-262 months). Patient 5 underwent unilateral DBS re 162 median DBS duration was 65 months (range, 7-262 months). Patient 5 underwent unilateral DBS removal
163 (extension and battery) 16 years after bilateral implantation due to a neck infection surrounding the left-163 (extension and battery) 16 years after bilateral implantation due to a neck infection surrounding the left-
164 sided extension wire. No intracranial infection was identified. He was successfully reimplanted 3 months 164 sided extension wire. No intracranial infection was identified. He was successfully reimplanted 3 months
165 later after adequate infection management with replacement of the left STN lead and extension and 165 later after adequate infection management with replacement of the left STN lead and extension and
166 battery replacement. Patient 8 had a right lead incision/burr hole erosion and infection necessitating 166 battery replacement. Patient 8 had a right lead incision/burr hole erosion and infection necessitating
167 complete bilateral DBS hardware removal 13 months after implantation. No intracranial infection was 167 complete bilateral DBS hardware removal 13 months after implantation. No intracranial infection was
168 identified At last follow-up, the TEED increased in 5 of 7 patients with available data by a mean of 15 identified At last follow-up, the TEED increased in 5 of 7 patients with available data by a mean of 151 169 J⋅s compared to their initial DBS settings. However, in patients 8 and 9, the TEED decreased slightly (1 170 and 21 J⋅s, respectively) from their initial parameters. A mean LEDD reduction of 28% was observed in 7
171 patients after DBS began. On the other hand, LEDD increased in patients 4 and 6 by 67% and >100%. patients after DBS began. On the other hand, LEDD increased in patients 4 and 6 by 67% and >100%,
172 respectively. Additional details about the LEDD and TEED are presented in **Supplemental Table 2**. In 172 respectively. Additional details about the LEDD and TEED are presented in **Supplemental Table 2**. In
173 terms of mortality. 1 patient (11%, case 9) passed away due to disease progression, 4 (44%) died due to 173 terms of mortality, 1 patient (11%, case 9) passed away due to disease progression, 4 (44%) died due to unknown causes, and the remaining 4 (44%) passed away due to reasons unrelated to the primary disease 174 unknown causes, and the remaining 4 (44%) passed away due to reasons unrelated to the primary disease
175 or an unknown cause. 175 or an unknown cause.
176

¹⁷⁷**Postmortem neurohistopathological characteristics**

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

178 An example of the gross and microscopic findings is presented in **Figure 1 (A-E)**. **Table 1** shows a descriptive summary of the postmortem neurohistopathologic findings. All patients except 2 showed 179 descriptive summary of the postmortem neurohistopathologic findings. All patients except 2 showed
180 gliosis at the DBS lead site. One of the 2 only had DBS for 7 months due to a fatal fall, while the other 180 gliosis at the DBS lead site. One of the 2 only had DBS for 7 months due to a fatal fall, while the other
181 showed no gliosis despite DBS for 140 months. Activated microglial infiltration was seen around the le 181 showed no gliosis despite DBS for 140 months. Activated microglial infiltration was seen around the lead
182 in 1 patient. For the 7 patients who developed gliosis around the DBS lead, the median DBS duration was in 1 patient. For the 7 patients who developed gliosis around the DBS lead, the median DBS duration was 183 65 months (range, 13-262). TEED increased over time in 4 patients (mean of 178 J⋅s) and decreased in 2 184 (1 and 21 J⋅s, respectively). A mean LEDD reduction of 32% was observed in 5/7 patients after DBS
185 compared to pre-operative values. Two patients required an increase of their LEDD over time of 67% 185 compared to pre-operative values. Two patients required an increase of their LEDD over time of 67% and
186 >100%, including the lone PD patient treated with globus pallidus interna DBS. Notable 186 >100%, including the lone PD patient treated with globus pallidus interna DBS. Notable
187 neurohistopathologic changes from the tissue sections are the following: substantia nigra 187 neurohistopathologic changes from the tissue sections are the following: substantia nigra depigmentation
188 was found in 2 (22%) patients (cases: 1 and 3) and nigra cell loss in 7 (78%; cases: 1, 4, 5, 6, 7, 8, and 9) was found in 2 (22%) patients (cases: 1 and 3) and nigra cell loss in 7 (78%; cases: 1, 4, 5, 6, 7, 8, and 9).
189 Patient 1 had a combination of nigra depigmentation and nigra cell loss. There were a variety of 189 Patient 1 had a combination of nigra depigmentation and nigra cell loss. There were a variety of additional neurodegenerative pathologic findings, including the presence of Lewy bodies in 5 pa 190 additional neurodegenerative pathologic findings, including the presence of Lewy bodies in 5 patients
191 (56%; cases: 2, 3, 4, 5, and 6) at different anatomical structures, neurofibrillary tangles in 4 (44%; case 191 (56%; cases: 2, 3, 4, 5, and 6) at different anatomical structures, neurofibrillary tangles in 4 (44%; cases: 192 5, 6, 8, and 9), tau aggregates in 4 (44%; cases: 2, 5, 8, and 9), beta-amyloid plaques in 3 (33%; cases 192 5, 6, 8, and 9), tau aggregates in 4 (44%; cases: 2, 5, 8, and 9), beta-amyloid plaques in 3 (33%; cases: 5,
193 6, and 8), TDP-43 inclusions in 2 (22%; cases: 2 and 5), and inclusions of alpha-synuclein in 1 (11%, cas 193 6, and 8), TDP-43 inclusions in 2 (22%; cases: 2 and 5), and inclusions of alpha-synuclein in 1 (11%, case
194 9). Of note, all but one assessed patients with 12 years or longer of PD duration at the time of death 1949). Of note, all but one assessed patients with 12 years or longer of PD duration at the time of death showed Lewy bodies. Finally, other pathological findings (distant to the tract) including hemorrhage 195 showed Lewy bodies. Finally, other pathological findings (distant to the tract) including hemorrhages and
196 subacute infarcts were reported in 3 (33%) patients (cases 6, 7, and 8). subacute infarcts were reported in 3 (33%) patients (cases 6, 7, and 8).

197
198

198 Systematic review update: study selection and characteristics
199 The literature review yielded 1249 articles, from which 18 du

199 The literature review yielded 1249 articles, from which 18 duplicates were removed. As a result of the initial screening by title and abstract, there were 48 potentially eligible articles. In the full-text

200 the initial screening by title and abstract, there were 48 potentially eligible articles. In the full-text evaluation, 16 documents were excluded for the following reasons: ineligible study type $(n=6)$,

201 evaluation, 16 documents were excluded for the following reasons: ineligible study type $(n=6)$,
202 insufficient data available $(n=5)$, ineligible outcomes $(n=3)$, and ineligible patient population $(n=6)$

202 insufficient data available ($n=5$), ineligible outcomes ($n=3$), and ineligible patient population ($n=2$).
203 Ultimately, 32 studies (25 case reports and 7 case series) from the final systematic search were inclu

203 Ultimately, 32 studies (25 case reports and 7 case series) from the final systematic search were included.
204 From the studies, a total of 59 patients who had a postmortem neurohistopathological assessment

204 From the studies, a total of 59 patients who had a postmortem neurohistopathological assessment
205 after DBS implantation (for different conditions) were identified. The studies were performed between

205 after DBS implantation (for different conditions) were identified. The studies were performed between
206 1977 and 2021. Fifteen were conducted in Europe $67,10,17-28$, 13 in North America²⁹⁻⁴¹, 3 in Australia⁴²⁻⁴⁴

1977 and 2021. Fifteen were conducted in Europe $6,7,10,17-28$, 13 in North America²⁹⁻⁴¹, 3 in Australia⁴²⁻⁴⁴, 207 and 1 in Asia⁴⁵. The number of patients per study ranged from 1 to 8. In terms of the conditions for

- and 1 in Asia⁴⁵. The number of patients per study ranged from 1 to 8. In terms of the conditions for which
208. DBS was implanted, 26 (44%) patients were treated for PD between 1994 and 2021 (Table 2; 2 MSA
- 208 DBS was implanted, 26 (44%) patients were treated for PD between 1994 and 2021 (**Table 2**; 2 MSA cases were initially misdiagnosed as PD), 6 (10%) for epilepsy (4 cases had cerebellar stimulation)
- cases were initially misdiagnosed as PD), 6 (10%) for epilepsy (4 cases had cerebellar stimulation)
210 between 1979 and 2020 (**Supplemental material Table 3**), 20 (34%) for pain between 1977 and 19
- ²¹⁰between 1979 and 2020 (**Supplemental material Table 3**), 20 (34%) for pain between 1977 and 1991

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- 211 (**Supplemental material Table 4**), and 7 (12%) for other conditions (tremor, chorea-acanthocytosis, and diffuse Lewy body disease) between 2000 and 2011 (**Supplemental material Table 5**).
- ²¹²diffuse Lewy body disease) between 2000 and 2011 (**Supplemental material Table 5**).
- 213
214

214 **Literature PD patients: DBS characteristics**
215 Regarding the 26 PD patients (cases 11^{18} and 26 PD patients

Regarding the 26 PD patients (cases 11^{18} and 15^{30} were confirmed to be MSA on autopsy), the age at 216 DBS implantation ranged from 24 to 81 years, and most were males (21; 81%). The DBS targets were the 216 DBS implantation ranged from 24 to 81 years, and most were males (21; 81%). The DBS targets were the subthalamic nucleus in 16 (62%) patients (15 bilateral and 1 left side), the ventralis intermedius thalamic 217 subthalamic nucleus in 16 (62%) patients (15 bilateral and 1 left side), the ventralis intermedius thalamic
218 uncleus in 8 (31%; 3 bilateral, 3 right, 2 left, and 1 unknown), the left centromedian-parafasicular 218 nucleus in 8 (31%; 3 bilateral, 3 right, 2 left, and 1 unknown), the left centromedian-parafasicular
219 complex thalamic region in 1 (4%), and the bilateral zona incerta in 1 (4%). Platinum/iridium elec 219 complex thalamic region in 1 (4%), and the bilateral zona incerta in 1 (4%). Platinum/iridium electrodes
220 vere the most emploved. DBS duration ranged from 2 days to 144 months. Three cases passed away were the most employed. DBS duration ranged from 2 days to 144 months. Three cases passed away
221 within 1 month after DBS implantation. Case 9 passed away 2 days after implantation due to myocare 221 within 1 month after DBS implantation. Case 9 passed away 2 days after implantation due to myocardial
222 infarction.¹⁰ Case 11 was readmitted 19 days after lead placement surgery due to abnormal behavior. infarction.¹⁰ Case 11 was readmitted 19 days after lead placement surgery due to abnormal behavior,
223 impaired gait, fever, and lethargy. DBS was discontinued, and medical management was started.¹⁸ impaired gait, fever, and lethargy. DBS was discontinued, and medical management was started.¹⁸
224 However, after transient improvement, the patient died 2 days later due to a massive pulmonary en 224 However, after transient improvement, the patient died 2 days later due to a massive pulmonary embolism
225 (identified in autonsy). Case 13 died 4 days after implantation due to cardiorespiratory arrest secondary to 225 (identified in autopsy). Case 13 died 4 days after implantation due to cardiorespiratory arrest secondary to pulmonary embolus (identified in autopsy). Clinical efficacy (as reported by the authors of each study) 226 pulmonary embolus (identified in autopsy). Clinical efficacy (as reported by the authors of each study)
227 was observed in 24 patients (92%), and decline was reported in 4 (15%). Death causes were diverse. was observed in 24 patients (92%), and decline was reported in 4 (15%). Death causes were diverse.
228 However, none of them were encountered intraoperatively during DBS implantation. 228 However, none of them were encountered intraoperatively during DBS implantation.
229

230 Literature PD patients: postmortem neurohistopathological characteristics
231 In terms of the postmortem neurohistopathological analysis, fibrillary gliosi

231 In terms of the postmortem neurohistopathological analysis, fibrillary gliosis (which represents a chronic tissue reaction) was reported in 23/24 (92%) patients, and in 2/26 (8%) patients, it could not be 232 chronic tissue reaction) was reported in 23/24 (92%) patients, and in 2/26 (8%) patients, it could not be
233 assessed due to precipitated death (details discussed above). In the patients who passed away within 1 233 assessed due to precipitated death (details discussed above). In the patients who passed away within 1
234 month after implantation, fresh hemorrhage was evidenced in 2/3 (67%). Reactive astrocytosis (mostly 234 month after implantation, fresh hemorrhage was evidenced in 2/3 (67%). Reactive astrocytosis (mostly
235 reflective of an acute tissue reaction) was observed in 14/25 (56%) patients. Microglial activation was 235 reflective of an acute tissue reaction) was observed in 14/25 (56%) patients. Microglial activation was
236 found in 9/17 (53%) patients, and neuronal loss was observed in 7/19 (37%) patients. Multinucleated 236 found in 9/17 (53%) patients, and neuronal loss was observed in 7/19 (37%) patients. Multinucleated giant cells were reported in $8/25$ (32%) patients. Regarding the pathologic findings of PD, nigra 237 giant cells were reported in 8/25 (32%) patients. Regarding the pathologic findings of PD, nigra
238 depigmentation was reported in 24/24 (100%) patients, and nigra cell loss in 21 (81%). Of note, 238 depigmentation was reported in 24/24 (100%) patients, and nigra cell loss in 21 (81%). Of note, in the
239 cases where MSA was confirmed on autopsy (2/26, 8%), DBS showed clinical efficacy only in case 11 cases where MSA was confirmed on autopsy (2/26, 8%), DBS showed clinical efficacy only in case 11.
240

241 **DISCUSSION**
242 In this stud

242 In this study of the neurohistopathological findings of 9 patients implanted with platinum/iridium
243 DBS electrodes for parkinsonism (1 patient), PD (7 patients), and parkinsonian type MSA (1 patient), v 243 DBS electrodes for parkinsonism (1 patient), PD (7 patients), and parkinsonian type MSA (1 patient), we found that at a median time of 65 months after DBS implantation, the brain tissue surrounding the DBS found that at a median time of 65 months after DBS implantation, the brain tissue surrounding the DBS

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

resulted in gliosis in 7 patients (78%) and the presence of activated microglia in 1 patient (11%). In
246 general, these results are consistent with previous postmortem studies showing that a glial response 246 general, these results are consistent with previous postmortem studies showing that a glial response is
247 consistently generated around the DBS electrodes. Additionally, our systematic review spanning betwers 247 consistently generated around the DBS electrodes. Additionally, our systematic review spanning between
248 1977 and 2021 of postmortem neuropathological studies reporting findings after DBS identified 59 248 1977 and 2021 of postmortem neuropathological studies reporting findings after DBS identified 59
249 unique patients who underwent treatment for PD, epilepsy, pain, and other conditions such as tremo 249 unique patients who underwent treatment for PD, epilepsy, pain, and other conditions such as tremor,
250 chorea-acanthocytosis, and diffuse Lewy body disease. As the number of patients treated with DBS (f 250 chorea-acanthocytosis, and diffuse Lewy body disease. As the number of patients treated with DBS (for a
251 wide variety of conditions) increases and the technologies continue to evolve, our study represents an 251 wide variety of conditions) increases and the technologies continue to evolve, our study represents an addition to the body of evidence on the postmortem findings after DBS and represents the most 252 addition to the body of evidence on the postmortem findings after DBS and represents the most
253 comprehensive and current review of this topic. 253 comprehensive and current review of this topic.
254

²⁵⁵**Gliosis surrounding the implantation site**

256 The presence of a gliotic response surrounding the DBS electrode described in this study is similar to
257 the findings reported in previous postmortem human studies and animal models.² Yet, our rate of 78% the findings reported in previous postmortem human studies and animal models.² Yet, our rate of 78%
258 (7/9 patients) gliotic response after a range of 7-262 months following DBS implantation is lower than 258 (7/9 patients) gliotic response after a range of 7-262 months following DBS implantation is lower than the
259 overall rate of gliotic responses reported in the literature (92%, 22/24 patients). Notably, one of our 259 overall rate of gliotic responses reported in the literature (92%, 22/24 patients). Notably, one of our patients without gliosis had DBS for 7 months. Previous studies have attributed the reaction of the b 260 patients without gliosis had DBS for 7 months. Previous studies have attributed the reaction of the brain
261 parenchyma to the electrode itself and/or the chronic stimulation.³² More study is needed to understand if parenchyma to the electrode itself and/or the chronic stimulation.³² More study is needed to understand if these factors, such as the biocompatibility of the implanted electrodes, the variability in the stimulation 262 these factors, such as the biocompatibility of the implanted electrodes, the variability in the stimulation
263 parameters, degradation of the metal contacts, and the length of stimulation (and others), could be 263 parameters, degradation of the metal contacts, and the length of stimulation (and others), could be implicated in the process of gliotic scar formation. The clinical implication (effect upon efficacy 264 implicated in the process of gliotic scar formation. The clinical implication (effect upon efficacy
265 variation) of the gliotic response around the DBS electrode is poorly described. The plausibility t 265 variation) of the gliotic response around the DBS electrode is poorly described. The plausibility that an
266 increased gliotic response negatively affects DBS efficacy seems reasonable and intuitive. However, in 266 increased gliotic response negatively affects DBS efficacy seems reasonable and intuitive. However, in
267 our study, from the 7 patients who developed gliotic changes, 5 had a 32% reduction in their LEDD at the 267 our study, from the 7 patients who developed gliotic changes, 5 had a 32% reduction in their LEDD at the 2 has 1 ast follow-up compared to pre-DBS dosage. This contrasted with the 2 patients who needed a greater 268 last follow-up compared to pre-DBS dosage. This contrasted with the 2 patients who needed a greater
269 than 50% LEDD increase over their post-implantation course. Of note, these patients (4 and 6 from Ta 269 than 50% LEDD increase over their post-implantation course. Of note, these patients (4 and 6 from Table 270 1) had the lowest pre-DBS LEDD levels and a prolonged DBS treatment (65 and 94 months, 270 1) had the lowest pre-DBS LEDD levels and a prolonged DBS treatment (65 and 94 months,
271 respectively). Also, patient 6 was the only one who received stimulation of the globus pallidu 271 respectively). Also, patient 6 was the only one who received stimulation of the globus pallidus interna,
272 which is known to not reduce LEDD after DBS compared to patients treated with STN DBS. Given the 272 which is known to not reduce LEDD after DBS compared to patients treated with STN DBS. Given the
273 variability in our findings, the limited sample size, and the lack of standardization in the assessment of 273 variability in our findings, the limited sample size, and the lack of standardization in the assessment of
274 values is a standard the DBS electrode, additional studies will be needed with objective clinical findings, 274 gliosis around the DBS electrode, additional studies will be needed with objective clinical findings, such
275 as LEDD and TEED, compared to in depth histological evaluation, such as volume and density of gliosis. 275 as LEDD and TEED, compared to in depth histological evaluation, such as volume and density of gliosis,
276 before robust conclusions can be made. Separating the gliosis produced by the implantation lesion and the 276 before robust conclusions can be made. Separating the gliosis produced by the implantation lesion and the
277 simulation-induced effects is also relevant for optimizing clinical efficacy. Thus, we recommend that 277 simulation-induced effects is also relevant for optimizing clinical efficacy. Thus, we recommend that
278 future studies evaluate the potential correlation between the gliotic scar and the clinical efficacy of DE future studies evaluate the potential correlation between the gliotic scar and the clinical efficacy of DBS

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- 279 treatment to provide needed insights for developing biocompatible materials, optimizing stimulation
280 parameters, and implantation techniques that optimize patient outcomes.
- 280 parameters, and implantation techniques that optimize patient outcomes.
281
-

²⁸²**Additional neurohistopathologic findings**

283 Evidence of additional markers of local tissue response (to the implanted electrodes), such as
284 activated microglia, reactive astrocytosis, giant multinuclear cells, hemosiderin-laden macrophages 284 activated microglia, reactive astrocytosis, giant multinuclear cells, hemosiderin-laden macrophages, and
285 neuronal loss, have been reported in previous studies.^{2,4,8} In our series, only one (11%) case (patient 2) neuronal loss, have been reported in previous studies.^{2,4,8} In our series, only one (11%) case (patient 2)
286 demonstrated activated microglia infiltration, which was lower than the 53% we found in the literature 286 demonstrated activated microglia infiltration, which was lower than the 53% we found in the literature
287 review. The presence of activated microglia lacks specificity but supports the presence of an ongoing 287 review. The presence of activated microglia lacks specificity but supports the presence of an ongoing
288 inflammatory response regardless of the chronicity of the electrode implantation. Furthermore, in the 288 inflammatory response regardless of the chronicity of the electrode implantation. Furthermore, in the literature review, we found additional tissue responses such as astrogliosis (53%), multinucleated gian 289 literature review, we found additional tissue responses such as astrogliosis (53%), multinucleated giant
290 cells (32%), and neuronal loss (37%). Although these findings are unspecific and were not assessed in c 290 cells (32%), and neuronal loss (37%). Although these findings are unspecific and were not assessed in our
291 series, their description, characterization, and role in the therapeutic action of DBS are of great interest 291 series, their description, characterization, and role in the therapeutic action of DBS are of great interest.
292 Support for more postmortem neurohistopathologic after DBS is also supported by our findings of change 292 Support for more postmortem neurohistopathologic after DBS is also supported by our findings of change
293 in diagnosis over time in our series and the literature. In our study 1 patient was confirmed to have MSA 293 in diagnosis over time in our series and the literature. In our study 1 patient was confirmed to have MSA after
294 after DBS implantation for PD, while in the literature, 2 cases^{18,30} had a similar update to MSA aft after DBS implantation for PD, while in the literature, 2 cases^{18,30} had a similar update to MSA after
295 bostmortem assessment. The lack of consistent efficacy in these cases confirms the need for an accur 295 postmortem assessment. The lack of consistent efficacy in these cases confirms the need for an accurate
296 diagnosis to obtain the best clinical results. Clinical research would benefit from pathologically confirme 296 diagnosis to obtain the best clinical results. Clinical research would benefit from pathologically confirmed
297 diagnosis to ensure data is accurate. Additional knowledge about DBS and its mechanisms could allow 297 diagnosis to ensure data is accurate. Additional knowledge about DBS and its mechanisms could allow
298 for the inclusion of other indications in which the therapy could have potential benefits. 298 for the inclusion of other indications in which the therapy could have potential benefits.
299

300 ³⁰⁰**Future directions**

301 Although the neurohistopathological changes observed in the tissue surrounding the DBS electrodes
302 show characteristics of a classical foreign body reaction, the presence of additional changes (around the 302 show characteristics of a classical foreign body reaction, the presence of additional changes (around the
303 active electrodes) and their underlying mechanisms are yet to be elucidated. The response of different 303 active electrodes) and their underlying mechanisms are yet to be elucidated. The response of different
304 cellular lines (neurons, glial cells, immune cells, and vasculature-related cells) to electrical stimulation 304 cellular lines (neurons, glial cells, immune cells, and vasculature-related cells) to electrical stimulation is
305 not established.¹ Determination of the influence of electrical currents (at varying intensities and not established.¹ Determination of the influence of electrical currents (at varying intensities and charge densities) on neuronal signaling, neural function, astrocyte response, and overall cellular metabolism 306 densities) on neuronal signaling, neural function, astrocyte response, and overall cellular metabolism
307 could provide valuable insights to tailor and optimize the stimulation parameters to favor minimal inj 307 could provide valuable insights to tailor and optimize the stimulation parameters to favor minimal injury,
308 maximal long-lasting efficacy, and expansion of the contemporary indications for DBS. Additionally, the 308 maximal long-lasting efficacy, and expansion of the contemporary indications for DBS. Additionally, the development and testing of electrodes (and coatings) with novel functional biomaterials aiming to 309 development and testing of electrodes (and coatings) with novel functional biomaterials aiming to
310 minimize the immune response, decrease tissue resistance to stimulation (impedance), favor the att 310 minimize the immune response, decrease tissue resistance to stimulation (impedance), favor the attraction
311 of the neuronal processes (potentially enhancing the benefits of DBS), and optimize the charge transfer 311 of the neuronal processes (potentially enhancing the benefits of DBS), and optimize the charge transfer
312 density. Such efforts are underway employing nanomaterials and nanoparticles that minimize the tissue density. Such efforts are underway employing nanomaterials and nanoparticles that minimize the tissue

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

reaction, favor neural recordings, and improve charge transfer efficiency.⁴⁶ Despite this, the use of
314 bostmortem neurohistopathological data continues to provide valuable and fundamental insights to 314 postmortem neurohistopathological data continues to provide valuable and fundamental insights to guide
315 future directions. However, the postmortem literature is largely dominated by studies with low-level 315 future directions. However, the postmortem literature is largely dominated by studies with low-level
316 evidence (case reports and case series), lacking standard tissue handling and assessment protocols. The 316 evidence (case reports and case series), lacking standard tissue handling and assessment protocols. The formation of an integrated network of researchers, the adoption of common protocols for the collection 317 formation of an integrated network of researchers, the adoption of common protocols for the collection
318 and management of specimens, and the implementation of new techniques for tissue evaluation seem to 318 and management of specimens, and the implementation of new techniques for tissue evaluation seem to
319 be the natural next step in the evolution of the study of human neurodegenerative and neuropsychiatric 319 be the natural next step in the evolution of the study of human neurodegenerative and neuropsychiatric disease and the role of DBS with them.^{47,48} 320 disease and the role of DBS with them.^{47,48} 321

321 ³²²**Limitations**

323 We acknowledge that our study has limitations. First, the sample size was small, and the analysis
324 was retrospective. Next, the clinical outcome data were limited by availability and patient follow-up was retrospective. Next, the clinical outcome data were limited by availability and patient follow-up
325 Additionally, the handling, processing, and evaluation of the neurohistopathological samples were 325 Additionally, the handling, processing, and evaluation of the neurohistopathological samples were
326 performed according to local protocols, which limits the comparison and generalizability of our fin 326 performed according to local protocols, which limits the comparison and generalizability of our findings.
327 Regarding the systematic review, the included studies were small (case reports and series) and 327 Regarding the systematic review, the included studies were small (case reports and series) and
328 retrospective. The clinical data and postmortem neurohistopathological findings were heteroge 328 retrospective. The clinical data and postmortem neurohistopathological findings were heterogeneously
329 reported based on the individual selection and preference of the authors from each study. However. 329 reported based on the individual selection and preference of the authors from each study. However,
330 considering the limited availability of such data and the lack of standardization on the protocols for 330 considering the limited availability of such data and the lack of standardization on the protocols for
331 neurohistopathological tissue handling, we included all the available reports aiming to comprehensi 331 neurohistopathological tissue handling, we included all the available reports aiming to comprehensively
332 summarize the existing literature. 332 summarize the existing literature.
333

333

334 **CONCLUSION**
335 Our findings

335 Our findings confirm the presence of a local tissue reaction, including gliosis and activated
336 microglial infiltration around the implanted DBS electrodes. The presence of additional histologi 336 microglial infiltration around the implanted DBS electrodes. The presence of additional histologic
337 changes has been reported in the literature however, the implication of these findings needs to be c 337 changes has been reported in the literature however, the implication of these findings needs to be clearly
338 established. The effect of the local changes on the clinical efficacy of DBS is not clearly established. As 338 established. The effect of the local changes on the clinical efficacy of DBS is not clearly established. As
339 the continual effort to expand the use, efficacy, and safety of DBS for neuromodulation and 339 the continual effort to expand the use, efficacy, and safety of DBS for neuromodulation and
340 neuros energy forward, the value of postmortem neurohistopathological evidence 340 neuroaugmentation moves forward, the value of postmortem neurohistopathological evidence will
341 undoubtedly shed more light on the mechanism behind this powerful clinical and surgical tool. Fur 341 undoubtedly shed more light on the mechanism behind this powerful clinical and surgical tool. Further
342 DBS postmortem studies and standardization of tissue processing are needed to expand the understandi 342 DBS postmortem studies and standardization of tissue processing are needed to expand the understanding
343 of the interaction between the local brain parenchyma and the implanted DBS electrode. 343 of the interaction between the local brain parenchyma and the implanted DBS electrode.
344

³⁴⁵**ACKNOWLEDGMENTS**

¹⁰

It is made available under a CC-BY-NC-ND 4.0 International license.

- 346 The authors would like to acknowledge the incredible contribution of the patient donors and their
347 families, as this research would not be possible without their generous gift to the advancement of s
- 347 families, as this research would not be possible without their generous gift to the advancement of science.
348 They would also like to acknowledge the support staff at the University of Iowa who worked tirelessly
- 348 They would also like to acknowledge the support staff at the University of Iowa who worked tirelessly
349 behind the scenes to keep our facilities running. If there are additional comments/suggestions, please let
- 349 behind the scenes to keep our facilities running. If there are additional comments/suggestions, please let
350 us know.
- us know.
- 351

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

352 REFERENCES
353 1. Evers J, I

- 353 1. Evers J, Lowery M. The Active Electrode in the Living Brain: The Response of the Brain
354 Parenchyma to Chronically Implanted Deep Brain Stimulation Electrodes. Oper Neurosurg
- 354 Parenchyma to Chronically Implanted Deep Brain Stimulation Electrodes. *Oper Neurosurg (Hagerstown)*. Jan 13 2021;20(2):131-140. doi:10.1093/ons/opaa326

³⁵⁵*(Hagerstown)*. Jan 13 2021;20(2):131-140. doi:10.1093/ons/opaa326

- 2. Orlowski D, Michalis A, Glud AN, et al. Brain Tissue Reaction to Deep Brain Stimulation-A
357 Longitudinal Study of DBS in the Goettingen Minipig. *Neuromodulation*. Jul 2017:20(5):417-423.
- 357 Longitudinal Study of DBS in the Goettingen Minipig. *Neuromodulation*. Jul 2017;20(5):417-423.
358 doi:10.1111/ner.12576
- 358 doi:10.1111/ner.12576
359 3. Fenov AJ, Goe
- 359 3. Fenoy AJ, Goetz L, Chabardès S, Xia Y. Deep brain stimulation: are astrocytes a key driver
360 behind the scene? CNS Neurosci Ther. Mar 2014;20(3):191-201. doi:10.1111/cns.12223
- 360 behind the scene? *CNS Neurosci Ther*. Mar 2014;20(3):191-201. doi:10.1111/cns.12223
361 4. DiLorenzo DJ. Jankovic J. Simpson RK. Takei H. Powell SZ. Neurohistopatholo
- 361 4. DiLorenzo DJ, Jankovic J, Simpson RK, Takei H, Powell SZ. Neurohistopathological findings at the electrode-tissue interface in long-term deep brain stimulation: systematic literature review, case
- 362 the electrode-tissue interface in long-term deep brain stimulation: systematic literature review, case
363 report, and assessment of stimulation threshold safety. *Neuromodulation*. Jul 2014;17(5):405-18;

363 report, and assessment of stimulation threshold safety. *Neuromodulation*. Jul 2014;17(5):405-18;
364 discussion 418. doi:10.1111/ner.12192

- 364 discussion 418. doi:10.1111/ner.12192
365 5. Moss J, Ryder T, Aziz TZ, Gra
- 365 5. Moss J, Ryder T, Aziz TZ, Graeber MB, Bain PG. Electron microscopy of tissue adherent to
366 explanted electrodes in dystonia and Parkinson's disease. *Brain*. Dec 2004:127(Pt 12):2755-63.
- 366 explanted electrodes in dystonia and Parkinson's disease. *Brain*. Dec 2004;127(Pt 12):2755-63.
367 doi:10.1093/brain/awh292
- 367 doi:10.1093/brain/awh292
368 6. Al-Helli O. Thoma
- 368 6. Al-Helli O, Thomas DL, Massey L, et al. Deep brain stimulation of the subthalamic nucleus:
369 histological verification and 9.4-T MRI correlation. Acta Neurochir (Wien). Dec 2015;157(12):2143-
- 369 histological verification and 9.4-T MRI correlation. *Acta Neurochir (Wien)*. Dec 2015;157(12):2143-7.
370 doi:10.1007/s00701-015-2599-x
- 370 doi:10.1007/s00701-015-2599-x
371 7. De Vloo P, Thal D, van I

371 7. De Vloo P, Thal D, van Kuyck K, Nuttin B. Histopathology after microelectrode recording and
372 twelve years of deep brain stimulation. *Brain Stimul*. Sep-Oct 2018;11(5):1183-1186. 372 twelve years of deep brain stimulation. *Brain Stimul*. Sep-Oct 2018;11(5):1183-1186.
373 doi:10.1016/j.brs.2018.05.005

- 373 doi:10.1016/j.brs.2018.05.005
374 8. Vedam-Mai V, Rodge
- 374 8. Vedam-Mai V, Rodgers C, Gureck A, et al. Deep Brain Stimulation associated gliosis: A post-
375 mortem study. Parkinsonism Relat Disord. Sep 2018;54:51-55. doi:10.1016/j.parkreldis.2018.04.009

375 mortem study. *Parkinsonism Relat Disord*. Sep 2018;54:51-55. doi:10.1016/j.parkreldis.2018.04.009
376 9. Vedam-Mai V. Martinez-Ramirez D. Hilliard JD. et al. Post-mortem Findings in Huntington's 376 9. Vedam-Mai V, Martinez-Ramirez D, Hilliard JD, et al. Post-mortem Findings in Huntington's
377 Deep Brain Stimulation: A Moving Target Due to Atrophy. *Tremor Other Hyperkinet Mov (N Y)*.

377 Deep Brain Stimulation: A Moving Target Due to Atrophy. *Tremor Other Hyperkinet Mov (N Y)*.
378 2016;6:372. doi:10.7916/d8zp462h

- 378 2016;6:372. doi:10.7916/d8zp462h
379 10. Haberler C, Alesch F, Maza
- 379 10. Haberler C, Alesch F, Mazal PR, et al. No tissue damage by chronic deep brain stimulation in
380 Parkinson's disease. Ann Neurol. Sep 2000:48(3):372-6.
- 380 Parkinson's disease. *Ann Neurol*. Sep 2000;48(3):372-6.
381 11. Tomlinson CL. Stowe R. Patel S. Rick C. Grav I 381 11. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa
382 dose equivalency reporting in Parkinson's disease. Mov Disord. Nov 15 2010;25(15):2649-53.
- 382 dose equivalency reporting in Parkinson's disease. *Mov Disord*. Nov 15 2010;25(15):2649-53.
383 doi:10.1002/mds.23429
- ³⁸³doi:10.1002/mds.23429

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- 384 12. Koss AM, Alterman RL, Tagliati M, Shils JL. Calculating total electrical energy delivered by
385 deep brain stimulation systems. Ann Neurol. Jul 2005;58(1):168; author reply 168-9.
- 385 deep brain stimulation systems. *Ann Neurol*. Jul 2005;58(1):168; author reply 168-9.
386 doi:10.1002/ana.20525
- 386 doi:10.1002/ana.20525
387 13. Fiock KL, Hoo
- 387 13. Fiock KL, Hook J, Hefti MM. Determinants of Astrocytic Pathology in Stem Cell Models of 388 Primary Tauopathies. *bioRxiv*. Jul 26 2023:doi:10.1101/2023.07.18.549558
- 388 Primary Tauopathies. *bioRxiv*. Jul 26 2023;doi:10.1101/2023.07.18.549558
389 14. Fiock KL, Smalley ME, Crary JF, Pasca AM, Hefti MM. Increased
- 389 14. Fiock KL, Smalley ME, Crary JF, Pasca AM, Hefti MM. Increased Tau Expression Correlates
390 with Neuronal Maturation in the Developing Human Cerebral Cortex. *eNeuro*. May/Jun
- 390 with Neuronal Maturation in the Developing Human Cerebral Cortex. *eNeuro*. May/Jun
391 2020:7(3)doi:10.1523/eneuro.0058-20.2020
- 391 2020;7(3)doi:10.1523/eneuro.0058-20.2020
392 15. Conway KS, Ghafoor F, Gottschalk
- 392 15. Conway KS, Ghafoor F, Gottschalk AC, et al. The Neuropathology of 1p36 Deletion Syndrome:
393 An Autopsy Case Series. *J Neuropathol Exp Neurol*. Sep 27 2021:80(9):856-860.
- 393 An Autopsy Case Series. *J Neuropathol Exp Neurol*. Sep 27 2021;80(9):856-860.
394 doi:10.1093/jnen/nlab072
- 394 doi:10.1093/jnen/nlab072
395 16. Wohlin C. Guideli
- 395 16. Wohlin C. Guidelines for snowballing in systematic literature studies and a replication in
396 software engineering. presented at: Proceedings of the 18th International Conference on Evaluation
- software engineering. presented at: Proceedings of the 18th International Conference on Evaluation and
397 Assessment in Software Engineering; 2014; London, England, United Kingdom.
- 397 Assessment in Software Engineering; 2014; London, England, United Kingdom.
398 https://doi.org/10.1145/2601248.2601268
- 398 https://doi.org/10.1145/2601248.2601268
399 17. Caparros-Lefebvre D, Ruchoux M
- 399 17. Caparros-Lefebvre D, Ruchoux MM, Blond S, Petit H, Percheron G. Long-term thalamic
400 stimulation in Parkinson's disease: postmortem anatomoclinical study. *Neurology*. Oct 1994:44(10)
- 400 stimulation in Parkinson's disease: postmortem anatomoclinical study. *Neurology*. Oct 1994;44(10):1856-401 60. doi:10.1212/wnl.44.10.1856
- 401 60. doi:10.1212/wnl.44.10.1856
402 18. Berciano J. Valldeoriola
- 18. Berciano J, Valldeoriola F, Ferrer I, et al. Presynaptic parkinsonism in multiple system atrophy
103 mimicking Parkinson's disease: a clinicopathological case study. Mov Disord. Jul 2002;17(4):812-6.
- 403 mimicking Parkinson's disease: a clinicopathological case study. *Mov Disord*. Jul 2002;17(4):812-6.
404 doi:10.1002/mds.10190
- 404 doi:10.1002/mds.10190
405 19. Jarraya B, Bonn
- 19. Jarraya B, Bonnet AM, Duyckaerts C, et al. Parkinson's disease, subthalamic stimulation, and
406 selection of candidates: a pathological study. Mov Disord. Dec 2003;18(12):1517-20.
- 406 selection of candidates: a pathological study. *Mov Disord*. Dec 2003;18(12):1517-20.
407 doi:10.1002/mds.10607
- 407 doi:10.1002/mds.10607
408 20. Nielsen MS, Bia
- 20. Nielsen MS, Bjarkam CR, Sørensen JC, Bojsen-Møller M, Sunde NA, Østergaard K. Chronic
409 subthalamic high-frequency deep brain stimulation in Parkinson's disease--a histopathological study. E
- 409 subthalamic high-frequency deep brain stimulation in Parkinson's disease--a histopathological study. *Eur 10 J Neurol.* Feb 2007;14(2):132-8. doi:10.1111/j.1468-1331.2006.01569.x
- ⁴¹⁰*J Neurol*. Feb 2007;14(2):132-8. doi:10.1111/j.1468-1331.2006.01569.x
- 411 21. Guehl D, Vital A, Cuny E, et al. POSTMORTEM PROOF OF EFFECTIVENESS OF ZONA
412 INCERTA STIMULATION IN PARKINSON DISEASE. Neurology. 2008;70(16 Part 2):1489-1490.
- 412 INCERTA STIMULATION IN PARKINSON DISEASE. *Neurology*. 2008;70(16 Part 2):1489-1490.
413 doi:10.1212/01.wnl.0000310426.18409.11
- 413 doi:10.1212/01.wnl.0000310426.18409.11
414 22. Gelpi E, Haberler C, Micko A, et a
- 414 22. Gelpi E, Haberler C, Micko A, et al. Focal Subthalamic Atrophy after Long-Term Deep Brain
415 Stimulation in Parkinson's Disease. *Mov Disord*. Aug 2021;36(8):1987-1989. doi:10.1002/mds.28653
- ⁴¹⁵Stimulation in Parkinson's Disease. *Mov Disord*. Aug 2021;36(8):1987-1989. doi:10.1002/mds.28653

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- 416 23. Wright GD, Weller RO. Biopsy and post-mortem findings in a patient receiving cerebellar
417 stimulation for epilepsy. *J Neurol Neurosurg Psychiatry*. Mar 1983:46(3):266-73.
- 417 stimulation for epilepsy. *J Neurol Neurosurg Psychiatry*. Mar 1983;46(3):266-73.
418 doi:10.1136/jnnp.46.3.266
- 418 doi:10.1136/jnnp.46.3.266
419 24. Giordano F, Capor
- 24. Giordano F, Caporalini C, Peraio S, et al. Post-mortem histopathology of a pediatric brain after
420 bilateral DBS of GPI for status dystonicus: case report and review of the literature. *Childs Nerv Syst*. Sep
- 420 bilateral DBS of GPI for status dystonicus: case report and review of the literature. *Childs Nerv Syst*. Sep
421 2020:36(9):1845-1851. doi:10.1007/s00381-020-04761-w
- 421 2020;36(9):1845-1851. doi:10.1007/s00381-020-04761-w
422 25. Gybels J, Dom R, Cosyns P. Electrical stimulation
- 422 25. Gybels J, Dom R, Cosyns P. Electrical stimulation of the central gray for pain relief in human:
423 autopsy data. Acta Neurochir Suppl (Wien). 1980:30:259-68. doi:10.1007/978-3-7091-8592-6. 31
- autopsy data. *Acta Neurochir Suppl (Wien)*. 1980;30:259-68. doi:10.1007/978-3-7091-8592-6_31
424 26. Boivie J, Meyerson BA. A correlative anatomical and clinical study of pain suppression b
- 424 26. Boivie J, Meyerson BA. A correlative anatomical and clinical study of pain suppression by deep
425 brain stimulation. *Pain*. Jun 1982:13(2):113-126. doi:10.1016/0304-3959(82)90022-7
- 425 brain stimulation. *Pain*. Jun 1982;13(2):113-126. doi:10.1016/0304-3959(82)90022-7
426 27. Burbaud P, Vital A, Rougier A, et al. Minimal tissue damage after stimulation
- 27. Burbaud P, Vital A, Rougier A, et al. Minimal tissue damage after stimulation of the motor
427 thalamus in a case of chorea-acanthocytosis. Neurology. Dec 24 2002;59(12):1982-4.
- ⁴²⁷thalamus in a case of chorea-acanthocytosis. *Neurology*. Dec 24 2002;59(12):1982-4.
- 428 doi:10.1212/01.wnl.0000038389.30437.1e
429 28. Valldeoriola F, Tolosa E, Alegret N
- 28. Valldeoriola F, Tolosa E, Alegret M, et al. Cognitive changes in Parkinson's disease during
430 subthalamic stimulation: a clinicopathologic study. *J Neurol Neurosurg Psychiatry*. Apr 2006:77(4)
- 430 subthalamic stimulation: a clinicopathologic study. *J Neurol Neurosurg Psychiatry*. Apr 2006;77(4):565-431 6. doi:10.1136/jnnp.2005.077990
- 431 6. doi:10.1136/jnnp.2005.077990
432 29. Counelis GJ, Simuni T, Fo
- 29. Counelis GJ, Simuni T, Forman MS, Jaggi JL, Trojanowski JQ, Baltuch GH. Bilateral
433 subthalamic nucleus deep brain stimulation for advanced PD: correlation of intraoperative MEI
- 433 subthalamic nucleus deep brain stimulation for advanced PD: correlation of intraoperative MER and
434 oostoperative MRI with neuropathological findings. *Mov Disord*. Sep 2003:18(9):1062-5.
- postoperative MRI with neuropathological findings. *Mov Disord*. Sep 2003;18(9):1062-5.
435 doi:10.1002/mds.10489
- 435 doi:10.1002/mds.10489
436 30. Chou KL, Form
- 436 30. Chou KL, Forman MS, Trojanowski JQ, Hurtig HI, Baltuch GH. Subthalamic nucleus deep brain
437 stimulation in a patient with levodopa-responsive multiple system atrophy. Case report. *J Neurosurg*. Mar
- 437 stimulation in a patient with levodopa-responsive multiple system atrophy. Case report. *J Neurosurg*. Mar
438 2004;100(3):553-6. doi:10.3171/jns.2004.100.3.0553
- 438 2004;100(3):553-6. doi:10.3171/jns.2004.100.3.0553
439 31. Sun DA, Yu H, Spooner J, et al. Postmortem 439 31. Sun DA, Yu H, Spooner J, et al. Postmortem analysis following 71 months of deep brain
440 stimulation of the subthalamic nucleus for Parkinson disease. *J Neurosurg*. Aug 2008:109(2):325-
- 440 stimulation of the subthalamic nucleus for Parkinson disease. *J Neurosurg*. Aug 2008;109(2):325-9.
441 doi:10.3171/ins/2008/109/8/0325
- 441 doi:10.3171/jns/2008/109/8/0325
442 32. Vedam-Mai V, Yachnis A
- 442 32. Vedam-Mai V, Yachnis A, Ullman M, Javedan SP, Okun MS. Postmortem observation of
443 collagenous lead tip region fibrosis as a rare complication of DBS. Mov Disord. Apr 2012;27(4):56
- collagenous lead tip region fibrosis as a rare complication of DBS. *Mov Disord*. Apr 2012;27(4):565-9.
444 doi:10.1002/mds.24916
- 444 doi:10.1002/mds.24916
445 33. Pilitsis JG. Chu
-
- 445 33. Pilitsis JG, Chu Y, Kordower J, Bergen DC, Cochran EJ, Bakay RA. Postmortem study of deep
446 brain stimulation of the anterior thalamus: case report. *Neurosurgery*. Feb 2008;62(2):E530-2; discussio 446 brain stimulation of the anterior thalamus: case report. *Neurosurgery*. Feb 2008;62(2):E530-2; discussion
447 E532. doi:10.1227/01.neu.0000316024.81786.78
- E532. doi:10.1227/01.neu.0000316024.81786.78

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- 448 34. Robertson LT, Dow RS, Cooper IS, Levy LF. Morphological changes associated with chronic
449 cerebellar stimulation in the human. *J Neurosurg*. Oct 1979;51(4):510-20.
- 449 cerebellar stimulation in the human. *J Neurosurg*. Oct 1979;51(4):510-20.
450 doi:10.3171/jns.1979.51.4.0510
- 450 doi:10.3171/jns.1979.51.4.0510
451 35. Hosobuchi Y, Adams JE
- 451 35. Hosobuchi Y, Adams JE, Linchitz R. Pain relief by electrical stimulation of the central gray
452 matter in humans and its reversal by naloxone. *Science*. Jul 8 1977;197(4299):183-6.
- 452 matter in humans and its reversal by naloxone. *Science*. Jul 8 1977;197(4299):183-6.
453 doi:10.1126/science.301658
- 453 doi:10.1126/science.301658
454 36. Baskin DS, Mehler V
- 454 36. Baskin DS, Mehler WR, Hosobuchi Y, Richardson DE, Adams JE, Flitter MA. Autopsy analysis
455 of the safety, efficacy and cartography of electrical stimulation of the central gray in humans. *Brain Res*.
- 455 of the safety, efficacy and cartography of electrical stimulation of the central gray in humans. *Brain Res*.
456 Apr 23 1986;371(2):231-6. doi:10.1016/0006-8993(86)90358-6
- 456 Apr 23 1986;371(2):231-6. doi:10.1016/0006-8993(86)90358-6
457 37. Boockvar JA. Telfeian A. Baltuch GH. et al. Long-term
- 457 37. Boockvar JA, Telfeian A, Baltuch GH, et al. Long-term deep brain stimulation in a patient with
458 essential tremor: clinical response and postmortem correlation with stimulator termination sites in ventra

458 essential tremor: clinical response and postmortem correlation with stimulator termination sites in ventral
459 thalamus. Case report. *J Neurosurg*. Jul 2000:93(1):140-4. doi:10.3171/ins.2000.93.1.0140

thalamus. Case report. *J Neurosurg*. Jul 2000;93(1):140-4. doi:10.3171/jns.2000.93.1.0140
38. Gross RE. Jones EG. Dostrovsky JO. Bergeron C. Lang AE. Lozano AM. Histologi

- 460 38. Gross RE, Jones EG, Dostrovsky JO, Bergeron C, Lang AE, Lozano AM. Histological analysis of
461 the location of effective thalamic stimulation for tremor. Case report. *J Neurosurg*. Mar 2004;100(3):547-
- the location of effective thalamic stimulation for tremor. Case report. *J Neurosurg*. Mar 2004;100(3):547-
462 52. doi:10.3171/ins.2004.100.3.0547
- 462 52. doi:10.3171/jns.2004.100.3.0547
463 39. McClelland S, 3rd, Vonsattel
- 463 39. McClelland S, 3rd, Vonsattel JP, Garcia RE, et al. Relationship of clinical efficacy to
464 postmortem-determined anatomic subthalamic stimulation in Parkinson syndrome. Clin Neuro
- 464 postmortem-determined anatomic subthalamic stimulation in Parkinson syndrome. *Clin Neuropathol*.
465 Nov-Dec 2007:26(6):267-75. doi:10.5414/npp26267
- 465 Nov-Dec 2007;26(6):267-75. doi:10.5414/npp26267
466 40. DiLorenzo DJ, Jankovic J, Simpson RK, Tak
- 466 40. DiLorenzo DJ, Jankovic J, Simpson RK, Takei H, Powell SZ. Long-term deep brain stimulation
467 for essential tremor: 12-year clinicopathologic follow-up. Mov Disord. Jan 30 2010;25(2):232-8.
- ⁴⁶⁷for essential tremor: 12-year clinicopathologic follow-up. *Mov Disord*. Jan 30 2010;25(2):232-8.
- 468 doi:10.1002/mds.22935
469 41. Hughes PS, Krc
- 41. Hughes PS, Krcek JP, Hobson DE, Del Bigio MR. An unusual inflammatory response to
470 implanted deep brain electrodes. Can J Neurol Sci. Jan 2011;38(1):168-70.
- 470 implanted deep brain electrodes. *Can J Neurol Sci*. Jan 2011;38(1):168-70.
471 42. Henderson JM, O'Sullivan DJ, Pell M, et al. Lesion of thalamic cer
- 471 42. Henderson JM, O'Sullivan DJ, Pell M, et al. Lesion of thalamic centromedian– parafascicular
472 complex after chronic deep brain stimulation. *Neurology*. 2001;56(11):1576-1579.
- 472 complex after chronic deep brain stimulation. *Neurology*. 2001;56(11):1576-1579.
473 doi:10.1212/wnl.56.11.1576
- 473 doi:10.1212/wnl.56.11.1576
474 43. Henderson JM, Pell 1
- 474 43. Henderson JM, Pell M, O'Sullivan DJ, et al. Postmortem analysis of bilateral subthalamic
475 electrode implants in Parkinson's disease. Mov Disord. Jan 2002;17(1):133-7. doi:10.1002/mds.12
- electrode implants in Parkinson's disease. *Mov Disord*. Jan 2002;17(1):133-7. doi:10.1002/mds.1261
476 44. Henderson J, Rodriguez M, O'Sullivan D, et al. Partial lesion of thalamic ventral intermediate
- 476 44. Henderson J, Rodriguez M, O'Sullivan D, et al. Partial lesion of thalamic ventral intermediate
477 uucleus after chronic high-frequency stimulation. *Mov Disord*. Jun 2004:19(6):709-11.
- 177 nucleus after chronic high-frequency stimulation. *Mov Disord*. Jun 2004;19(6):709-11.
478 doi:10.1002/mds.10709
- 478 doi:10.1002/mds.10709
479 45. Kuroda R. Naka
- 479 45. Kuroda R, Nakatani J, Yamada Y, Yorimae A, Kitano M. Location of a DBS-electrode in lateral
480 thalamus for deafferentation pain. An autopsy case report. Acta Neurochir Suppl (Wien). 1991;52:140-2.
- thalamus for deafferentation pain. An autopsy case report. *Acta Neurochir Suppl (Wien)*. 1991;52:140-2.
481 doi:10.1007/978-3-7091-9160-6 38
- ⁴⁸¹doi:10.1007/978-3-7091-9160-6_38

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- 482 46. Angelov SD, Koenen S, Jakobi J, et al. Electrophoretic deposition of ligand-free platinum
483 nanoparticles on neural electrodes affects their impedance in vitro and in vivo with no negative eff
- 183 nanoparticles on neural electrodes affects their impedance in vitro and in vivo with no negative effect on
184 neactive gliosis. *J Nanobiotechnology*. Jan 12 2016;14:3. doi:10.1186/s12951-015-0154-9
- 184 reactive gliosis. *J Nanobiotechnology*. Jan 12 2016;14:3. doi:10.1186/s12951-015-0154-9
185 47. Vedam-Mai V. Biovalue in Human Brain Banking: Applications and Challenges f
- 485 47. Vedam-Mai V. Biovalue in Human Brain Banking: Applications and Challenges for Research in
486 Neurodegenerative Diseases. *Methods Mol Biol.* 2022;2389:209-220. doi:10.1007/978-1-0716-1783-0_17
- 186 Neurodegenerative Diseases. *Methods Mol Biol.* 2022;2389:209-220. doi:10.1007/978-1-0716-1783-0_17
187 48. Vedam-Mai V, Krock N, Ullman M, et al. The national DBS brain tissue network pilot study:
- 48. Vedam-Mai V, Krock N, Ullman M, et al. The national DBS brain tissue network pilot study:
488 need for more tissue and more standardization. *Cell Tissue Bank*. Aug 2011;12(3):219-31.
- 188need for more tissue and more standardization. *Cell Tissue Bank*. Aug 2011;12(3):219-31.
489 doi:10.1007/s10561-010-9189-1
- ⁴⁸⁹doi:10.1007/s10561-010-9189-1

494 $\mathrm{^{a}}$ DBS duration was calculated from the first activation until removal or death. $\mathrm{^{b}}$ LEDD change from last follow-up versus pre-DBS. $\mathrm{^{c}}$ TEED change from last follow-up versus 6 (\pm 495 3) months. ^d An additional lead (VIM) was implanted due to refractory right-sided tremor after the initial bilateral STN stimulation. ^e 198 months after implantation, the patient underwent left battery and extension removal due to neck infection. Left STN lead replacement, extension, and battery re-implantation was performed 3 months later. The total time accounts only for the time when DBS stimula time accounts only for the time when DBS stimulation was active. ^f Entire DBS system removed due to right burr hole erosion and infection. 498

499 Abbreviations: B, bilateral; COPD, chronic obstructive pulmonary disease; DBS, deep brain stimulation; F, female; GPI, globus pallidus interna; LEDD, Levodopa equivalent 500 daily dose; M, male; MSA, multiple system atrophy; n., number; NA, not available, STN, subthalamic nucleus; TEED, total electrical energy delivered; VIM, ventral intermediate

501 nucleus.

491 **TABLES**

⁵⁰³ * DBS indicated for PD, but postmortem examination established diagnosis of multiple system atrophy
504 Abbreviations: BL, bilateral; CM-Pf, centromedian-parafasicular complex thalamic region; DBS, deep b

Abbreviations: BL, bilateral; CM-Pf, centromedian-parafasicular complex thalamic region; DBS, deep brain stimulation; F, female; L, left; M, male; n., number;

505 NR, not reported; Pt/Ir, platinum/iridium; R, right; STN, subthalamic nucleus; TUNEL, (TdT)-mediated UTP nick and labelling; Vim, ventralis intermedius
506 thalamic nucleus; ZI, zona incerta.

thalamic nucleus; ZI, zona incerta.

507

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

FIGURES AND FIGURE LEGENDS

Figure 1 (A-E). Macroscopic and microscopic tissue representations. (**A**) Coronal brain slice depicting gross bilateral tracts with close-up pop-out. Arrows denote tracts. (**B**) Hematoxylin & Eosin stain slide of midbrain with electrode tract in the nigra. Black scale = 200 µm. (**C**) Lewy bodies in the nigra, arrow denotes Lewy body. White scale = 50 µm. (**D**) Luxol fast blue stain on thalamus with electrode tract. Black scale = 200 µm. (**E**) Glial fibrillary acidic protein statin on thalamus with tract. Black scale $= 200 \mu m$.